Cargando…

Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib

BACKGROUND: Renal medullary carcinoma (RMC) is a rare but aggressive tumor often complicated by early lung metastasis with few treatment options and very poor outcomes. There are currently no verified RMC patient-derived xenograft (PDX) mouse models established from metastatic pleural effusion (PE)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Alex Q., Ijiri, Masami, Rodriguez, Ryan, Gandour-Edwards, Regina, Lee, Joyce, Tepper, Clifford G., Li, Yueju, Beckett, Laurel, Lam, Kit, Goodwin, Neal, Satake, Noriko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032976/
https://www.ncbi.nlm.nih.gov/pubmed/33842362
http://dx.doi.org/10.3389/fonc.2021.648097
_version_ 1783676323378495488
author Lee, Alex Q.
Ijiri, Masami
Rodriguez, Ryan
Gandour-Edwards, Regina
Lee, Joyce
Tepper, Clifford G.
Li, Yueju
Beckett, Laurel
Lam, Kit
Goodwin, Neal
Satake, Noriko
author_facet Lee, Alex Q.
Ijiri, Masami
Rodriguez, Ryan
Gandour-Edwards, Regina
Lee, Joyce
Tepper, Clifford G.
Li, Yueju
Beckett, Laurel
Lam, Kit
Goodwin, Neal
Satake, Noriko
author_sort Lee, Alex Q.
collection PubMed
description BACKGROUND: Renal medullary carcinoma (RMC) is a rare but aggressive tumor often complicated by early lung metastasis with few treatment options and very poor outcomes. There are currently no verified RMC patient-derived xenograft (PDX) mouse models established from metastatic pleural effusion (PE) available to study RMC and evaluate new therapeutic options. METHODS: Renal tumor tissue and malignant PE cells from an RMC patient were successfully engrafted into 20 NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ (NSG) mice. We evaluated the histopathological similarity of the renal tumor and PE PDXs with the original patient renal tumor and PE, respectively. We then evaluated the molecular integrity of the renal tumor PDXs between passages, as well as the PE PDX compared to two generations of renal tumor PDXs, by microarray analysis. The therapeutic efficacy of sunitinib and temsirolimus was tested in a serially-transplanted generation of 27 PE PDX mice. RESULTS: The pathologic characteristics of the patient renal tumor and patient PE were retained in the PDXs. Gene expression profiling revealed high concordance between the two generations of renal tumor PDXs (RMC-P0 vs. RMC-P1, r=0.865), as well as between the first generation PE PDX and each generation of the renal tumor PDX (PE-P0 vs. RMC-P0, r=0.919 and PE-P0 vs. RMC-P1, r=0.843). A low number (626) of differentially-expressed genes (DEGs) was seen between the first generation PE PDX and the first generation renal tumor PDX. In the PE-P1 xenograft, sunitinib significantly reduced tumor growth (p<0.001) and prolonged survival (p=0.004) compared to the vehicle control. CONCLUSIONS: A metastatic PE-derived RMC PDX model was established and shown to maintain histologic features of the patient cancer. Molecular integrity of the PDX models was well maintained between renal tumor and PE PDX as well as between two successive renal tumor PDX generations. Using the PE PDX model, sunitinib demonstrated therapeutic efficacy for RMC. This model can serve as a foundation for future mechanistic and therapeutic studies for primary and metastatic RMC.
format Online
Article
Text
id pubmed-8032976
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80329762021-04-10 Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib Lee, Alex Q. Ijiri, Masami Rodriguez, Ryan Gandour-Edwards, Regina Lee, Joyce Tepper, Clifford G. Li, Yueju Beckett, Laurel Lam, Kit Goodwin, Neal Satake, Noriko Front Oncol Oncology BACKGROUND: Renal medullary carcinoma (RMC) is a rare but aggressive tumor often complicated by early lung metastasis with few treatment options and very poor outcomes. There are currently no verified RMC patient-derived xenograft (PDX) mouse models established from metastatic pleural effusion (PE) available to study RMC and evaluate new therapeutic options. METHODS: Renal tumor tissue and malignant PE cells from an RMC patient were successfully engrafted into 20 NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ (NSG) mice. We evaluated the histopathological similarity of the renal tumor and PE PDXs with the original patient renal tumor and PE, respectively. We then evaluated the molecular integrity of the renal tumor PDXs between passages, as well as the PE PDX compared to two generations of renal tumor PDXs, by microarray analysis. The therapeutic efficacy of sunitinib and temsirolimus was tested in a serially-transplanted generation of 27 PE PDX mice. RESULTS: The pathologic characteristics of the patient renal tumor and patient PE were retained in the PDXs. Gene expression profiling revealed high concordance between the two generations of renal tumor PDXs (RMC-P0 vs. RMC-P1, r=0.865), as well as between the first generation PE PDX and each generation of the renal tumor PDX (PE-P0 vs. RMC-P0, r=0.919 and PE-P0 vs. RMC-P1, r=0.843). A low number (626) of differentially-expressed genes (DEGs) was seen between the first generation PE PDX and the first generation renal tumor PDX. In the PE-P1 xenograft, sunitinib significantly reduced tumor growth (p<0.001) and prolonged survival (p=0.004) compared to the vehicle control. CONCLUSIONS: A metastatic PE-derived RMC PDX model was established and shown to maintain histologic features of the patient cancer. Molecular integrity of the PDX models was well maintained between renal tumor and PE PDX as well as between two successive renal tumor PDX generations. Using the PE PDX model, sunitinib demonstrated therapeutic efficacy for RMC. This model can serve as a foundation for future mechanistic and therapeutic studies for primary and metastatic RMC. Frontiers Media S.A. 2021-03-26 /pmc/articles/PMC8032976/ /pubmed/33842362 http://dx.doi.org/10.3389/fonc.2021.648097 Text en Copyright © 2021 Lee, Ijiri, Rodriguez, Gandour-Edwards, Lee, Tepper, Li, Beckett, Lam, Goodwin and Satake https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lee, Alex Q.
Ijiri, Masami
Rodriguez, Ryan
Gandour-Edwards, Regina
Lee, Joyce
Tepper, Clifford G.
Li, Yueju
Beckett, Laurel
Lam, Kit
Goodwin, Neal
Satake, Noriko
Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib
title Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib
title_full Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib
title_fullStr Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib
title_full_unstemmed Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib
title_short Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib
title_sort novel patient metastatic pleural effusion-derived xenograft model of renal medullary carcinoma demonstrates therapeutic efficacy of sunitinib
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032976/
https://www.ncbi.nlm.nih.gov/pubmed/33842362
http://dx.doi.org/10.3389/fonc.2021.648097
work_keys_str_mv AT leealexq novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib
AT ijirimasami novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib
AT rodriguezryan novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib
AT gandouredwardsregina novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib
AT leejoyce novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib
AT teppercliffordg novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib
AT liyueju novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib
AT beckettlaurel novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib
AT lamkit novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib
AT goodwinneal novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib
AT satakenoriko novelpatientmetastaticpleuraleffusionderivedxenograftmodelofrenalmedullarycarcinomademonstratestherapeuticefficacyofsunitinib